Barry Rockx, Ph.D.
Assistant Professor, Department of Pathology
University of Texas Medical Branch
301 University Blvd,
Galveston, TX 77555-0610
Office: (409) 266-6904
Fax: (409) 266-6810
|Degree||Institution||Field of Study||Graduation Year|
Hogeschool West-Brabant, Etten-Leur, The Netherlands
|M.Sc.||Vrije Universiteit, Amsterdam, The Netherlands||Virology||1998|
Graduate School of Animal Health, Utrecht, The Netherlands
|Postdoctoral||University of North Carolina, Chapel Hill, NC||Virology||2004-2008|
|1999-2004||Ph.D. student, Diagnostic Laboratory for Infectious Diseases, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.|
|2004||Emanuel Wolinsky Award for best article published in Clinical Infectious Diseases in 2002.|
|2004||Post-doctoral Research associate, Diagnostic Laboratory for Infectious Diseases, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.|
|2004-2008||Post-Doctoral Research Associate, Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC|
|2008-2010||Research Fellow, Laboratory of Virology, Rocky Mountain Laboratories, DIR, NIAID, NIH|
|2010||Rising STAR award|
|2010-present||Assistant Professor, Departments of Pathology and Microbiolgy & Immunology, University of Texas Medical Branch, Galveston, TX|
Dr. Rockx’s research interests are focused on virus-host interactions, molecular pathogenic mechanisms, and the host responses following emerging high containment virus infection. His research will focus on the development and characterization of in vivo and in vitro models of Hendra (HeV) and Nipah virus (NiV) infection. HeV and NiV are two members of the genus Henipavirus (family Paramyxoviridea) that cause respiratory illness and encephalitis in humans and a variety of other mammals. The goal of these projects is to understand how these viruses infect the respiratory tract and spread to the central nervous system and to identify differences in routes of transmission and pathogenesis between different HeV and NiV strains.
A second area of interest is the development and testing of broadly protective therapeutics. The high mutation rate and heterogeneity of emerging zoonotic viruses is a major problem in developing therapeutics and therefore a key objective is the development of broadly cross-reactive reagents that will maximize the likelihood of protection against unknown future strain variants.
Articles in Peer-Reviewed Journals: